News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
690,900 Results
Type
Article (39527)
Company Profile (311)
Press Release (651062)
Section
Business (204843)
Career Advice (2010)
Deals (35490)
Drug Delivery (91)
Drug Development (81048)
Employer Resources (168)
FDA (16128)
Job Trends (14863)
News (345942)
Policy (32561)
Tag
Academia (2548)
Alliances (49532)
Alzheimer's disease (1265)
Approvals (16087)
Artificial intelligence (144)
Bankruptcy (354)
Best Places to Work (11604)
Biotechnology (218)
Breast cancer (189)
Cancer (1375)
Cardiovascular disease (110)
Career advice (1677)
Cell therapy (283)
Clinical research (64828)
Collaboration (487)
Compensation (262)
COVID-19 (2557)
C-suite (110)
Data (1392)
Diabetes (175)
Diagnostics (6191)
Earnings (85035)
Employer resources (146)
Events (110546)
Executive appointments (398)
FDA (16814)
Funding (430)
Gene therapy (195)
GLP-1 (602)
Government (4347)
Healthcare (18719)
Infectious disease (2650)
Inflammatory bowel disease (115)
Interviews (309)
IPO (16379)
Job creations (3660)
Job search strategy (1431)
Layoffs (423)
Legal (7896)
Lung cancer (198)
Lymphoma (98)
Manufacturing (208)
Medical device (13224)
Medtech (13229)
Mergers & acquisitions (19274)
Metabolic disorders (460)
Neuroscience (1587)
NextGen Class of 2024 (6536)
Non-profit (4480)
Northern California (1701)
Obesity (261)
Opinion (187)
Patents (119)
People (56791)
Phase I (20182)
Phase II (28561)
Phase III (21271)
Pipeline (514)
Postmarket research (2561)
Preclinical (8577)
Radiopharmaceuticals (236)
Rare diseases (263)
Real estate (5936)
Regulatory (21745)
Research institute (2317)
Resumes & cover letters (350)
Southern California (1473)
Startups (3616)
United States (15248)
Vaccines (566)
Weight loss (183)
Date
Today (79)
Last 7 days (547)
Last 30 days (2331)
Last 365 days (35355)
2024 (35196)
2023 (40181)
2022 (51291)
2021 (55837)
2020 (54160)
2019 (46650)
2018 (35129)
2017 (32227)
2016 (31631)
2015 (37709)
2014 (31454)
2013 (26500)
2012 (28777)
2011 (29431)
2010 (27528)
Location
Africa (716)
Arizona (195)
Asia (37483)
Australia (6135)
California (3843)
Canada (1453)
China (307)
Colorado (172)
Connecticut (177)
Europe (80362)
Florida (536)
Georgia (135)
Illinois (388)
Indiana (226)
Maryland (632)
Massachusetts (2976)
Michigan (174)
Minnesota (291)
New Jersey (1104)
New York (1088)
North Carolina (744)
Northern California (1701)
Ohio (148)
Pennsylvania (926)
South America (1095)
Southern California (1473)
Texas (555)
Utah (108)
Washington State (402)
690,900 Results for "greenwich biosciences inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Greenwich LifeSciences Partners with GIM in Italy
November 26, 2024
·
8 min read
Press Releases
Greenwich LifeSciences Provides Update on Corporate Events
November 18, 2024
·
5 min read
Lone Star Bio
Greenwich LifeSciences Set to Join Russell 2000 Index Again
Greenwich LifeSciences, Inc. announced that it is set to join the Russell 2000 and Russell 3000 Indexes at the conclusion of the Russell indexes annual reconstitution, effective after the US markets open on July 1, 2024, according to a list of additions updated as of June 21, 2024.
June 26, 2024
·
5 min read
Lone Star Bio
Greenwich LifeSciences Announces $2.5 Million Private Placement
Greenwich LifeSciences, Inc. announced that it has entered into a securities purchase agreement with its Chief Executive Officer, Snehal Patel, for the purchase and sale of 174,825 shares of its common stock at a purchase price of $14.30 per share in a private placement.
June 14, 2024
·
4 min read
Drug Development
Greenwich LifeSciences Flamingo-01 Manufacturing & Protocol Accepted by European Regulators
Greenwich LifeSciences, Inc. provided the following update on the expansion of the clinical trial into Europe.
February 22, 2024
·
5 min read
Business
Greenwich LifeSciences Extends Lock-up of Directors and Officers to June 30, 2025
Greenwich LifeSciences, Inc. announced that its Board of Directors has extended the lock-up of the shares owned by the Company’s directors, officers, and existing pre-IPO investors to June 30, 2025 which is approximately 57 months from date of the Company’s IPO.
March 13, 2024
·
4 min read
Drug Development
Greenwich LifeSciences Partners with GEICAM in Spain & Conducts First Site Initiation Visits in Europe
Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, announced the initiation of the first clinical sites in Europe in collaboration with GEICAM in Spain.
March 12, 2024
·
10 min read
Drug Development
Greenwich LifeSciences Provides Update on Phase III Clinical Trial, Flamingo-01
Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company focused on the development of GLSI-100, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery, provided the following update on the Phase III clinical trial, Flamingo-01.
February 14, 2024
·
26 min read
Drug Development
Greenwich LifeSciences Flamingo-01 Phase III Clinical Trial Approved to Expand into Five Largest European Countries
Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, provided the following update on the expansion of the clinical trial into Europe.
February 27, 2024
·
5 min read
Press Releases
Greenwich LifeSciences Provides Update on Expansion of Flamingo-01 into Spain
August 1, 2024
·
6 min read
1 of 69,090
Next
